Kim Kramer

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Chronic neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 95:1366-75. 2002
  2. ncbi request reprint Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    Matthias Miederer
    Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6985-92. 2004
  3. pmc Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY 10065, USA
    J Neurooncol 97:409-18. 2010
  4. doi request reprint Establishing successful cerebrospinal fluid flow for radioimmunotherapy
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurosurg Pediatr 9:316-9. 2012
  5. ncbi request reprint Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8
    K Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:716-8. 2000
  6. ncbi request reprint Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5465-70. 2007
  7. ncbi request reprint Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation
    Kim Kramer
    Department of Pediatrics, Sloan Kettering Cancer Center, New York, New York, USA
    J Pediatr Hematol Oncol 26:703-5. 2004
  8. ncbi request reprint Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 25:601-5. 2003
  9. pmc A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:1340-2. 2009
  10. ncbi request reprint High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007

Research Grants

  1. Treating CNS malignancies with 131-I-8H9
    Kim Kramer; Fiscal Year: 2006
  2. 131-1 3F8 FOR LEPTOMENINGEAL CANCERS
    Kim Kramer; Fiscal Year: 2007
  3. 131-1 3F8 FOR LEPTOMENINGEAL CANCERS
    Kim Kramer; Fiscal Year: 2006
  4. 131-1 3F8 FOR LEPTOMENINGEAL CANCERS
    Kim Kramer; Fiscal Year: 2008

Detail Information

Publications56

  1. ncbi request reprint Chronic neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 95:1366-75. 2002
    ..An indolent course is associated with neuroblastoma (NB) in adolescents and adults. In the current study, the authors analyzed this phenomenon in a large series of children with metastatic NB...
  2. ncbi request reprint Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    Matthias Miederer
    Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6985-92. 2004
    ..The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis...
  3. pmc Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY 10065, USA
    J Neurooncol 97:409-18. 2010
    ..The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies. It has the potential to increase survival with better than expected quality of life...
  4. doi request reprint Establishing successful cerebrospinal fluid flow for radioimmunotherapy
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurosurg Pediatr 9:316-9. 2012
    ..Endoscopic third ventriculostomy can be considered in patients with programmable shunting devices; normal or slit ventricles do not preclude successful ETV...
  5. ncbi request reprint Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8
    K Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 35:716-8. 2000
    ..Intrathecal antibody-based targeted therapies may have clinical potential for patients with leptomeningeal (LM) cancer...
  6. ncbi request reprint Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5465-70. 2007
    ..We tested the toxicity, pharmacokinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) targeting GD2-positive CNS/LM disease in a phase I clinical trial...
  7. ncbi request reprint Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation
    Kim Kramer
    Department of Pediatrics, Sloan Kettering Cancer Center, New York, New York, USA
    J Pediatr Hematol Oncol 26:703-5. 2004
    ..This case illustrates that some infants with favorable-biology neuroblastoma may be observed without treatment despite the advanced INSS stage...
  8. ncbi request reprint Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 25:601-5. 2003
    ..Although toxicity was generally thought to be mild, the efficacy of such an approach remains unproven...
  9. pmc A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:1340-2. 2009
    ..The falx cerebri probably does not represent an atypical site for stage 4S NB, but stage 4 NB with favorable biology is sometimes curable with minimal therapy...
  10. ncbi request reprint High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007
    ..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients...
  11. ncbi request reprint Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 120:2050-9. 2014
    ..The authors exploited a large database to investigate the outcomes of patients with high-risk neuroblastoma in the contemporary era...
  12. ncbi request reprint Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma
    Sonal Bhandari
    Department of Pediatrics, New York Presbyterian Weill Cornell Medical College, New York, New York, USA
    Pediatr Blood Cancer 55:76-80. 2010
    ..To determine the prevalence of and risk factors for primary hypothyroidism following treatment with a radiolabeled monoclonal antibody ((131)I-3F8) in children with neuroblastoma...
  13. ncbi request reprint Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:4888-92. 2004
    ..We now describe similar results with changes that reduce toxicity (fewer cycles, less vincristine, use of granulocyte colony-stimulating factor)...
  14. ncbi request reprint Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 75:1181-6. 2009
    ..To present a large experience (73 patients) using a standard radiotherapy (RT) protocol to prevent relapse in cranial sites where measurable metastatic neuroblastoma (NB), an adverse prognostic marker, is common...
  15. pmc Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 27:1041-6. 2009
    ..Relapse-free survival (RFS) is a powerful measure of treatment efficacy. We describe the sensitivity of standard surveillance studies for detecting relapse of neuroblastoma (NB)...
  16. pmc Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 53:17-22. 2009
    ..We report a prospective study of secondary leukemia (SL)/myelodysplastic syndrome (MDS) in neuroblastoma (NB) patients treated with > or =5 cycles of dose-intensive chemotherapy...
  17. ncbi request reprint Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma
    Irene Y Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1087-93. 2003
    ..Because therapy (myeloablation, immunotherapy, or differentiation) for MRD is applied at the time of clinical remission, objective surrogate markers are needed to gauge treatment efficacy...
  18. ncbi request reprint Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 116:3054-60. 2010
    ....
  19. doi request reprint High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
  20. ncbi request reprint Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:84-7. 2004
    ..The aim was to use a regimen with little risk to major organs to (a) achieve or consolidate remission in heavily treated patients and to (b) induce an immunological state conducive to passive immunotherapy with the murine 3F8 antibody...
  21. pmc Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomography
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 26:4995-6. 2008
  22. doi request reprint Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
    Victoria J Croog
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 78:849-54. 2010
    ..This study describes the use of craniospinal irradiation (CSI) for CNS relapse and compares outcomes to patients who received focal radiotherapy (RT)...
  23. pmc Management and outcome of stage 3 neuroblastoma
    Shakeel Modak
    Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 45:90-8. 2009
    ..We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB...
  24. ncbi request reprint Marker (+) CNS germ cell tumors in remission: are surveillance MRI scans necessary?
    Sybila Martinez
    Memorial Sloan Kettering Cancer Center, New York, New York, 10065
    Pediatr Blood Cancer 61:853-4. 2014
    ..We hypothesized that patients with elevated serum tumor markers at diagnosis who achieve a complete biochemical and radiological remission may not need surveillance MRI scans...
  25. ncbi request reprint Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Pediatr Oncol 41:508-15. 2003
    ..We reviewed the utility of different treatment modalities in a large series of adolescents/adults with neuroblastoma (NB)...
  26. ncbi request reprint Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5271-6. 2006
    ..To report on an irinotecan and temozolomide regimen for neuroblastoma (NB). Quality of life and minimizing toxicity were major considerations...
  27. ncbi request reprint Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1271-3. 2008
    ..5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia...
  28. doi request reprint Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer 119:665-71. 2013
    ..A major reason for using this regimen was the long time since patients received previous treatment with a platinum compound. The authors also summarized the published experience on ICE in patients with NB...
  29. pmc Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid
    Ping He
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA corrected
    Eur J Nucl Med Mol Imaging 38:334-42. 2011
    ..We now describe a two-compartment model to account for the ventricular reservoir of (131)I-3F8 and to identify limiting factors that may impact therapeutic ratio...
  30. doi request reprint High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur J Cancer 47:84-9. 2011
    ..We used a novel regimen for neuroblastoma (NB) that had responded inadequately to standard chemotherapy which now includes topotecan in induction or second-line therapy...
  31. ncbi request reprint Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer 119:2789-95. 2013
    ..In this report, the authors describe PRES associated with antidisialoganglioside (anti-GD2 ) monoclonal antibody (MoAb) immunotherapy, which is now standard for high-risk neuroblastoma but has not previously been implicated in PRES...
  32. ncbi request reprint Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 46:278-84. 2006
    ..We reviewed clinical and biologic findings in a series of infants with neuroblastoma (NB) in liver. The aim was to gain insights into improving therapy...
  33. ncbi request reprint Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:417-22. 2006
    ....
  34. pmc Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 51:552-4. 2008
    ..Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR...
  35. ncbi request reprint Long-term complications in survivors of advanced stage neuroblastoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pediatr Blood Cancer 45:324-32. 2005
    ..Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease...
  36. pmc Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 30:3264-70. 2012
    ..Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored...
  37. pmc Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:1168-74. 2011
    ..We hypothesized that 3F8 dose escalation is possible without increased analgesic requirements in patients pretreated with HM3F8...
  38. ncbi request reprint Treatment of spinal involvement in neuroblastoma patients
    David I Sandberg
    Department of Surgery, Division of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, N Y 10021, USA
    Pediatr Neurosurg 39:291-8. 2003
    ..Considerable controversy exists regarding the appropriate management of spinal involvement in neuroblastoma (NB) patients. We review a large group of such patients and offer treatment recommendations...
  39. ncbi request reprint Key role for myeloid cells: Phase II results of anti-GD2 antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma
    Nai Kong V Cheung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
    Int J Cancer 135:2199-205. 2014
    ..MRD response may be an indicator of tumor sensitivity to anti-GD2 immunotherapy. Correlative studies highlight the antineoplastic potency of myeloid effectors. ..
  40. ncbi request reprint The impact of gross total resection on local control and survival in high-risk neuroblastoma
    Michael P La Quaglia
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pediatr Surg 39:412-7; discussion 412-7. 2004
    ..The authors reviewed their institutional experience to assess the effect of primary tumor resection on local control and overall survival...
  41. ncbi request reprint Brain-sparing radiotherapy for neuroblastoma skull metastases
    Suzanne L Wolden
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:1163-8. 2008
    ..The purpose of this study was to describe the technique, outcome and toxicities in patients with high risk NB metastatic to the skull treated with brain-sparing skull radiotherapy (BSRT)...
  42. ncbi request reprint Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Pediatr Hematol Oncol 26:35-9. 2004
    ..Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy...
  43. ncbi request reprint Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy
    Brian H Kushner
    Departments of Medical Imaging and Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:1082-6. 2003
    ..We present the first report on the effect of MIBG scans on the classification of response to dose-intensive induction therapy...
  44. ncbi request reprint Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:858-62. 2005
    ..Quality of life was a major issue in choosing this regimen for patients whose disease was resistant to standard anti-NB therapies...
  45. ncbi request reprint Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Pediatr Hematol Oncol 25:515-9. 2003
    ..The authors report on a series of patients who had distant recurrences after surgery alone for local-regional neuroblastoma...
  46. doi request reprint Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Pediatr Blood Cancer 58:469-71. 2012
    ..Hematopoietic reconstitution was achieved in all three patients receiving plerixafor-primed stem cells after myeloablative therapy. Plerixafor is an effective and safe agent for stem cell collection in patients with NB...
  47. doi request reprint Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections
    Mark L Kayton
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Pediatr Surg 45:1961-6. 2010
    ..Catheter-related bloodstream infections remain costly with no simple prevention. We report preliminary results of a phase I trial of ethanol-lock administration to prevent mediport catheter-related bloodstream infections in children...
  48. ncbi request reprint Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission
    Brian H Kushner
    Authors Affiliations Departments of Pediatrics and Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 20:1375-82. 2014
    ..gov NCT00911560). Secondary objectives were to obtain preliminary data on immune response and activity against minimal residual disease (MRD). Treatment also included the immunostimulant β-glucan...
  49. ncbi request reprint Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates
    Matthias Miederer
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:129-37. 2004
    ..However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG...
  50. ncbi request reprint A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies
    Stephen W Gilheeney
    Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Pediatr Blood Cancer 49:261-5. 2007
    ..This trial was undertaken to investigate whether the combination of cyclophosphamide and thalidomide would be active against pediatric tumors...
  51. ncbi request reprint Large congenital melanotic nevi in an extremity with neurocutaneous melanocytosis
    Oren J Becher
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
    Pediatr Dermatol 26:79-82. 2009
    ..In our case, cerebrospinal fluid studies were not reliable even in the face of florid neurocutaneous melanocytosis involving the leptomeninges and ventricles...
  52. ncbi request reprint High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecan
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Pediatr Blood Cancer 56:403-8. 2011
    ..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
  53. ncbi request reprint Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies
    Kim Kramer
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Pediatr Blood Cancer 61:1590-2. 2014
    ..The use of Ommaya catheters or ventriculoperitoneal shunts with programmable valves (pVP-shunts) for intraventricular drug administration is increasingly more common...
  54. doi request reprint Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients
    Richard K G Do
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Pediatr Radiol 41:335-40. 2011
    ..FNH can be incidentally found on CT and MRI and can be misdiagnosed as liver metastasis in patients with an oncological history...
  55. ncbi request reprint Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia
    James B Bussel
    Department of Pediatrics, The New York Hospital, Cornell University Medical Center, New York, New York 10021, USA
    Pediatr Blood Cancer 45:176-83. 2005
    ..This study was undertaken to compare the outcome of cases of AIT to cases of neonatal thrombocytopenia shown not to be AIT and to identify clinical features that would facilitate the diagnosis...
  56. ncbi request reprint Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects
    Bruno De Bernardi
    Department of Haematology Oncology, Giannina Gaslini Children s Hospital, Largo Gerolamo Gaslini, 5, 16148 Genova, Italy
    Cancer Lett 228:283-99. 2005
    ....

Research Grants4

  1. Treating CNS malignancies with 131-I-8H9
    Kim Kramer; Fiscal Year: 2006
    ..abstract_text> ..
  2. 131-1 3F8 FOR LEPTOMENINGEAL CANCERS
    Kim Kramer; Fiscal Year: 2007
    ..This study will be the basis for other regional therapies using radiolabeled-antibodies targeting tumor associated antigens for other CNS malignancies. [unreadable] [unreadable]..
  3. 131-1 3F8 FOR LEPTOMENINGEAL CANCERS
    Kim Kramer; Fiscal Year: 2006
    ..This study will be the basis for other regional therapies using radiolabeled-antibodies targeting tumor associated antigens for other CNS malignancies. [unreadable] [unreadable]..
  4. 131-1 3F8 FOR LEPTOMENINGEAL CANCERS
    Kim Kramer; Fiscal Year: 2008
    ..This study will be the basis for other regional therapies using radiolabeled-antibodies targeting tumor associated antigens for other CNS malignancies. [unreadable] [unreadable]..